The EMPrint™ Ablate and RESect Study in Patients With Metastatic Lung Tumors (EMPRESS)

Not Applicable

Completed

Brief Summary: Post market prospective, non-randomized, single-arm, multicenter study, designed to demonstrate dose response of an ablation system using a percutaneous approach in patients with primary, metastatic, or recurrent primary lung tumors.

Detailed Description: Primary Endpoint: Dose response as indicated by CT imaging, measurement of maximum diameter and volume.

Secondary Endpoint: Assessment of complete tumor ablation immediately post-procedure.

Recruitment & Eligibility

Inclusion Criteria

Subject or authorized representative has provided informed consent.
Subject is ≥18 years of age.
At least one pulmonary metastasis ≤ 3.0 cm in maximum diameter resulting from distant primary cancers or at least one recurrence of primary lung cancer ≤ 3.0 cm in maximum diameter.
Subject has been confirmed by a thoracic surgeon to be a surgical candidate for resection of the tumor targeted for ablation.
Subject is willing and able to comply with all aspects of the treatment and evaluation schedule.
≥1 cm of tumor-free lung parenchyma between target tumor and pleura or fissure.

Exclusion Criteria

Pre-procedure Exclusion Criteria
Contraindicated for surgery.
Prolonged chest infection, defined as lung consolidation that requires hospitalization and greater than 10 days of antibiotics 30 days prior to surgery.
Tumor abutting main stem bronchus, main pulmonary artery branches, esophagus and/or trachea.
Tumor with pleural contact.
Tumors located < 3 cm of staple lines or other metal objects.
Patients diagnosed with GOLD Stage IV Emphysema.
Uncontrollable coagulopathy
Patients unable to tolerate discontinued use of anti-coagulants prior to and during the ablation procedure.
Subject is pregnant (documented by a positive pregnancy test according to hospital standard practices) or is actively breast-feeding.
Subject has participated in an investigational drug or device research study within 30 days of enrollment that would interfere with this study.
The investigator determines that participation in the study may jeopardize the safety or welfare of the subject.
Patients with implantable pacemakers and other electronic implants, in accordance with Instructions for Use (IFU).

Intraprocedural Exclusion Criteria

*Incidental intraprocedural finding that the subject no longer meets the study eligibility criteria.

Arm && Interventions

Group	Intervention	Description
Ablation and Surgical Resection	Ablation	Ablation of lung tumor; followed by surgical resection of the ablation zone.
Ablation and Surgical Resection	Surgical Resection	Ablation of lung tumor; followed by surgical resection of the ablation zone.

Primary Outcome Measures

Name	Time	Method
Ablation Zone Shape	Same day	Ablation width (X) / height (Y), ratio of 1 indicates spherical ablation zone shape
Dose Response	1 Day	Dose response was assessed by comparing actual ablation zone size and volume to predicted ablation zone size and volume prescribed by the physician using the Emprint™ Procedure Planning Application. Dose response was measured for each ablation zone using CT imaging immediately post ablation and prior to the surgical resection.

Secondary Outcome Measures

Name	Time	Method
Number of Participants With Complete or Incomplete Tumor Ablation	Same Day	The secondary endpoint was complete tumor ablation immediately post-procedure for each target tumor using histologic analysis. Complete ablation was defined as 100% nonviable tumor cells.

Locations (4): Mayo Clinic
🇺🇸
Rochester, Minnesota, United States
University Hospital Frankfurt
🇩🇪
Frankfurt, Germany
Weill Cornell Medical College
🇺🇸
New York, New York, United States
Rhode Island Hospital
🇺🇸
Providence, Rhode Island, United States